Payment overview · 2025
General Payments
$611.90
36 reported records · 6 companies
Healthcare provider profile · identity verified
Rasa K Miller, MD
Allopathic & Osteopathic Physicians|Family Medicine · MC CALLA, AL · NPI 1982672952
Verified facts
What the public records show
CMS Open Payments records show Rasa K Miller, MD received $611.90 in general payments during 2025 across 36 reported records.
PFIZER INC. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $200.32 | 32.7% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $180.13 | 29.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.80 | 18.3% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $64.82 | 10.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.62 | 5.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.21 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $611.90 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $200.32 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $200.32 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $180.13 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $169.35 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $64.82 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.26 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.54 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 379 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 91 |
| Montelukast Sodium | Montelukast Sodium | 271 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 58 |
| Gabapentin | Gabapentin | 218 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 60 |
| Omeprazole | Omeprazole | 185 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 48 |
| Losartan Potassium | Losartan Potassium | 160 | 41 |
| Clonazepam | Clonazepam | 156 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 45 |
| Lisinopril | Lisinopril | 142 | 36 |
| Trazodone Hcl | Trazodone Hcl | 137 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 134 | 46 |
| Furosemide | Furosemide | 126 | 35 |
| Tramadol Hcl | Tramadol Hcl | 118 | 35 |
| Potassium Chloride | Potassium Chloride | 117 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 114 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 27 |
| Meloxicam | Meloxicam | 106 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 24 |
| Baclofen | Baclofen | 98 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 21 |
| Glimepiride | Glimepiride | 87 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 25 |
| Mirtazapine | Mirtazapine | 82 | 19 |
| Ozempic | Semaglutide | 82 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 25 |
| Carvedilol | Carvedilol | 78 | 18 |
| Metformin Hcl Er | Metformin Hcl | 75 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Metformin Hcl | Metformin Hcl | 73 | 26 |
| Eliquis | Apixaban | 70 | 16 |
| Pregabalin | Pregabalin | 70 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 22 |
| Clonidine Hcl | Clonidine Hcl | 64 | 16 |
| Simvastatin | Simvastatin | 64 | 17 |
| Glipizide Er | Glipizide | 61 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 22 |
| Allopurinol | Allopurinol | 57 | 14 |
| Famotidine | Famotidine | 57 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 12 |
| Jardiance | Empagliflozin | 55 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 16 |
| Sertraline Hcl | Sertraline Hcl | 53 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 16 |
| Alendronate Sodium | Alendronate Sodium | 50 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 14 |
| Methocarbamol | Methocarbamol | 50 | 21 |
| Donepezil Hcl | Donepezil Hcl | 49 | 11 |
| Bupropion Xl | Bupropion Hcl | 47 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 12 |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 13 |
| Linzess | Linaclotide | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Prednisone | Prednisone | 32 | 25 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Nabumetone | Nabumetone | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 19 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 14 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 20 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 12 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $611.90 · 36 records | PFIZER INC. | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error